G Spencer-Green

5.8k total citations · 2 hit papers
40 papers, 4.1k citations indexed

About

G Spencer-Green is a scholar working on Rheumatology, Pathology and Forensic Medicine and Epidemiology. According to data from OpenAlex, G Spencer-Green has authored 40 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Rheumatology, 15 papers in Pathology and Forensic Medicine and 7 papers in Epidemiology. Recurrent topics in G Spencer-Green's work include Rheumatoid Arthritis Research and Therapies (14 papers), Systemic Sclerosis and Related Diseases (12 papers) and Systemic Lupus Erythematosus Research (8 papers). G Spencer-Green is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (14 papers), Systemic Sclerosis and Related Diseases (12 papers) and Systemic Lupus Erythematosus Research (8 papers). G Spencer-Green collaborates with scholars based in United States, Canada and United Kingdom. G Spencer-Green's co-authors include Stanley Cohen, Michael H. Weisman, John T. Sharp, Ronald van Vollenhoven, John L. Perez, Ferdinand C. Breedveld, Arthur F. Kavanaugh, Karel Pavelká, Nemanja Damjanov and Robert S. Kauffman and has published in prestigious journals such as The Journal of Experimental Medicine, The American Journal of Medicine and Annals of the Rheumatic Diseases.

In The Last Decade

G Spencer-Green

38 papers receiving 3.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The PREMIER study: A multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment

2005 1.4k citations Ferdinand C. Breedveld, Michael H. Weisman et al. Arthritis & Rheumatism profile →
Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two‐year radiographic and clinical outcomes

2002 573 citations Mark C. Genovese, Joan M. Bathon et al. Arthritis & Rheumatism profile →

Peers

G Spencer-Green

RHEUM

HEMAT

PFM

IMMUN

Jeska K de Vries‐Bouwstra Netherlands

Maria Greenwald United States

Arthur F. Kavanaugh United States

Olivier Vittecoq France

Sudha Visvanathan United States

Carol A. Connell United States

Satoshi Kubo Japan

Jean‐Claude Becker United States

Terence Rooney United States

Anna Filipowicz‐Sosnowska Poland

Jeska K de Vries‐Bouwstra Netherlands

G Spencer-Green

2.8k ×1.0

RHEUM

995 ×0.9

HEMAT

914 ×1.0

PFM

568 ×0.6

IMMUN

265 ×0.5

Citations per year, relative to G Spencer-Green G Spencer-Green (= 1×) peers Jeska K de Vries‐Bouwstra

Countries citing papers authored by G Spencer-Green

Since Specialization

Citations

This map shows the geographic impact of G Spencer-Green's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G Spencer-Green with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G Spencer-Green more than expected).

Fields of papers citing papers by G Spencer-Green

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G Spencer-Green. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G Spencer-Green. The network helps show where G Spencer-Green may publish in the future.

Co-authorship network of co-authors of G Spencer-Green

This figure shows the co-authorship network connecting the top 25 collaborators of G Spencer-Green. A scholar is included among the top collaborators of G Spencer-Green based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G Spencer-Green. G Spencer-Green is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhu, Zhaohua, et al.. (2025). Extended and Controlled Release Liposomal Formulated Dexamethasone (TLC599) for Chronic Knee Osteoarthritis Pain (EXCELLENCE): A Phase 3, Randomized, Placebo-controlled Clinical Trial. Osteoarthritis and Cartilage. 33. S125–S126.

Cohen, Stanley, Paul Emery, Maria Greenwald, et al.. (2016). A phase I pharmacokinetics trial comparing PF‐05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis. British Journal of Clinical Pharmacology. 82(1). 129–138. 46 indexed citations

Damjanov, Nemanja, Robert S. Kauffman, & G Spencer-Green. (2009). Efficacy, pharmacodynamics, and safety of VX‐702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: Results of two randomized, double‐blind, placebo‐controlled clinical studies. Arthritis & Rheumatism. 60(5). 1232–1241. 187 indexed citations

Breedveld, Ferdinand C., Michael H. Weisman, Arthur F. Kavanaugh, et al.. (2005). The PREMIER study: A multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis & Rheumatism. 54(1). 26–37. 1390 indexed citations breakdown →

Matsos, Mark, Janet Pope, & G Spencer-Green. (2004). ANA+ (anti-nuclear antibody) is correlated with RF+ (rheumatoid factor) in rheumatoid arthritis. Inflammopharmacology. 12(3). 229–231. 1 indexed citations

Moreland, Larry W., R. Pat Bucy, Michael E. Weinblatt, et al.. (2002). Immune Function in Patients with Rheumatoid Arthritis Treated with Etanercept. Clinical Immunology. 103(1). 13–21. 45 indexed citations

Genovese, Mark C., Joan M. Bathon, Richard W. Martin, et al.. (2002). Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two‐year radiographic and clinical outcomes. Arthritis & Rheumatism. 46(6). 1443–1450. 573 indexed citations breakdown →

Spencer-Green, G. (2000). Etanercept (Enbrel): update on therapeutic use. Annals of the Rheumatic Diseases. 59. i46–i49. 59 indexed citations

Spencer-Green, G. (1998). Outcomes in Primary Raynaud Phenomenon. Archives of Internal Medicine. 158(6). 595–595. 150 indexed citations

10.

Spencer-Green, G, David Alter, & H. Gilbert Welch. (1997). Test Performance in Systemic Sclerosis. The American Journal of Medicine. 103(3). 242–248. 63 indexed citations

11.

Spencer-Green, G. (1994). Retinoic Acid Effects on Endothelial Cell Function: Interaction with Interleukin 1. Clinical Immunology and Immunopathology. 72(1). 53–61. 6 indexed citations

12.

Fava, Roy A., Nancy J. Olsen, G Spencer-Green, et al.. (1994). Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue.. The Journal of Experimental Medicine. 180(1). 341–346. 448 indexed citations

13.

Spencer-Green, G, et al.. (1994). Radiologic Vignette. Arthritis & Rheumatism. 37(3). 435–438. 3 indexed citations

14.

Spencer-Green, G, et al.. (1993). Augmentation of interleukin-1 induced prostacyclin production by endothelial cell growth factor: Implications for chronic synovitis. Prostaglandins. 45(5). 439–445. 2 indexed citations

15.

Spencer-Green, G. (1993). Drug treatment of arthritis. Postgraduate Medicine. 93(7). 129–140. 1 indexed citations

16.

FitzGerald, Oliver, Evelyn V. Hess, Gerald T. O’Connor, & G Spencer-Green. (1988). Prospective study of the evolution of Raynaud's phenomenon. The American Journal of Medicine. 84(4). 718–726. 66 indexed citations

17.

FitzGerald, Oliver, et al.. (1987). Esophageal motility studies in patients with Raynaud's phenomenon.. PubMed. 14(2). 273–7. 7 indexed citations

18.

Jw, Parker, et al.. (1985). T-lymphocyte subset phenotypes: a multisite evaluation of normal subjects and patients with AIDS.. PubMed. 3(2). 75–82. 14 indexed citations

19.

Spencer-Green, G, William Crowe, & Joseph E. Levinson. (1982). Nailfold capillary abnormalities and clinical outcome in childhood dermatomyositis. Arthritis & Rheumatism. 25(8). 954–958. 59 indexed citations

20.

Maricq, Hildegard R., G Spencer-Green, & E. Carwile LeRoy. (1976). Skin capillary abnormalities as indicators of organ involvement in scleroderma (systemic sclerosis), Raynaud's syndrome and dermatomyositis. The American Journal of Medicine. 61(6). 862–870. 142 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact